Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions

Ewa Szalowska1,3*, Tessa E. Pronk2 and Ad ACM Peijnenburg1

Abstract

Background: The transcription factor farnesoid X receptor (FXR) governs bile acid and energy homeostasis, is involved in inflammation, and has protective functions in the liver. In the present study we investigated the effect of Fxr deficiency in mouse precision cut liver slices (PCLS) exposed to a model hepatotoxicant cyclosporin A (CsA). It was anticipated that Fxr deficiency could aggravate toxicity of CsA in PCLS and pinpoint to novel genes/processes regulated by FXR.

Methods: To test this hypothesis, PCLS obtained from livers of wild type mice (WT-PCLS) and Fxr-knockout mice (FXRKO-PCLS) were treated with 40 μM CsA for 24 h and 48 h. ATP and histological assays were applied to assess the viability of PCLS. DNA microarrays combined with bioinformatics analysis were used to identify genes and processes that were affected by CsA in WT-PCLS and/or FXRKO-PCLS. In addition, WT-PCLS and FXRKO-PCLS were exposed to the endogenous FXR ligand chenodeoxycholic acid (CDCA) and subjected to q-PCR to determine whether subsets of known FXR-targets and the identified genes were regulated upon FXR activation in an FXR-dependent manner.

Results: No difference in viability was observed between WT-PCLS and FXRKO-PCLS upon CsA treatment. Transcriptomics data analysis revealed that CsA significantly upregulated stress-response and inflammation and significantly downregulated processes involved in lipid and glucose metabolism in WT-PCLS and FXRKO-PCLS. However, only in FXRKO-PCLS, CsA upregulated additional pro-inflammatory genes and downregulated genes related to mitochondrial functions. Furthermore, only in WT-PCLS, CDCA upregulated a subset of known FXR-target genes as well as the regulator of inflammation and mitochondrial functions peroxisome proliferator-activated receptor delta (Ppar delta).

(Continued on next page)
Background

Farnesoid X receptor (Fxr) is highly expressed in liver, intestine, kidney, adrenal glands and has a lower expression in white adipose tissue, pancreas, heart, and stomach [1]. Upon the discovery that bile acids (BA) are endogenous FXR agonists with chenodeoxy cholic acid (CDCA) being the most potent FXR agonist, the primary functions of FXR were attributed to the maintenance of BA homeostasis [2]. FXR, upon activation by binding of a ligand, dimerizes either as a homodimer or as an heterodimer with another member of the nuclear receptor superfamily, retinoid X receptor (RXR), and binds to FXR response elements (FXRE) in the promoter region of its target genes to drive transcription [2]. FXR positively regulates the expression of several genes coding transporters and enzymes involved in BA homeostasis including bile salt export pump (BSEP), bile acid-CoA:amino acid N-acyltransferase (BAAT), or multidrug resistance protein 3 (MDR3). In addition, FXR can inhibit the expression of some of its target genes, including cholesterol-7α-hydroxylase (Cyp7a1), by a mechanism referred to as trans-repression involving induction of other transcription factors, such as small heterodimer partner (Shp). Thus, in liver FXR upregulates its direct target gene Shp, which in turn inhibits expression of the liver receptor homolog (Lrh)-1, liver X receptor (Lxr), and hepatocyte nuclear factor 4 α (Hnf4α), all necessary for constitutive expression of Cyp7a1, coding a rate limiting enzyme in the synthesis of BA from cholesterol [3].

In recent years it has become evident that FXR, next to its well established role in BA homeostasis, is also involved in the maintenance of lipid and glucose metabolism [2]. Consistent with these observations, Fxr-knockout (KO) mice are dyslipidemic, with elevated plasma triglycerides and cholesterol levels [4]. With regard to regulation of glucose homeostasis, it was shown that Fxr-KO mice display peripheral insulin resistance implying that FXR is involved in regulation of insulin sensitivity and glucose metabolism [3]. In line with these findings, FXR was shown to regulate expression of the gluconeogenic genes such as phosphoenolpyruvate carboxykinase (Pepck) and glucose 6 phosphatase (G6Pase) [5, 6]. In addition to its role in BA and energy homeostasis, FXR exerts hepatoprotective functions through its anti-inflammatory, anti-fibrotic, anti-apoptotic, pro-regenerative, and detoxifying features [7].

Due to the complexity of hepatic FXR signaling, involving entero-hepatic communication and interplay with extrahepatic tissues [2], none of the current in vitro models allow to study FXR functions in full. However, it is possible to study mechanisms related to hepatic FXR signaling in in vitro liver models. One such model is represented by precision cut liver slices (PCLS). The major advantage of PCLS, compared to mono-cultures of hepatocytes, is the presence of parenchymal as well as non-parenchymal liver cells, whose interactions are important in the context of FXR signaling [8–11].

The objective of the present study was to investigate the role of FXR in the liver under a hepatotoxic challenge. It was anticipated that Fxr deficiency could aggravate effects of the model hepatotoxic compound cyclosporine A (CsA). CsA is an immunosuppressive drug commonly applied after solid organ transplantation to prevent rejection [12]. The pharmacological properties of CsA are related to repression of the activity of the immune system by interfering with T cell functioning [13, 14]. Adverse effects caused by CsA include hepatotoxicity that can lead to the development of cholestasis [15], fatty liver [16], and cardiovascular complications due to hyperlipidemia [17]. The primary mechanism of action underlying the hepatotoxicity of CsA is prevention of the mitochondrial permeability transition pore from opening leading to oxidative stress and impairment of mitochondrial functions [18]. This is most likely followed by induction of NFκB signaling driving expression of pro-inflammatory cytokines (e.g. TNFα, IL1α, and IL1β) and endoplasmatic reticulum (ER) stress, causing a disturbed vesicles formation necessary for protein, lipid, and bile acid trafficking [11, 19]. In addition, it was reported that expression of Fxr and its target genes was de-regulated upon treatment with CsA in different human and rodent in vitro liver models as well as rodents in vivo [11, 20–22].
In order to study the effect of Fxr deficiency under hepatotoxic challenge, mouse PCLS obtained from livers of wild type (WT) and Fxr-KO mice (referred to as WT-PCLS and FXRKO-PCLS, respectively) were treated with 40 μM CsA. ATP and histological assays were applied to assess the viability of the PCLS after 24 h and 48 h. DNA microarrays combined with bioinformatics analysis were used to identify genes and processes (i.e. pathways and gene ontology (GO) terms) that were affected in WT-PCLS and/or FXRKO-PCLS upon 24 h treatment with CsA. The genes and processes commonly affected in WT-PCLS and FXRKO-PCLS were considered as CsA targets, whose regulation was not dependent on FXR. The genes and processes that were significantly affected in either WT-PCLS or FXRKO-PCLS after CsA treatment were considered to be regulated in an FXR-dependent manner. To verify whether regulation of some of the identified genes was FXR-dependent, WT-PCLS and FXRKO-PCLS were exposed for 24 h to the endogenous FXR ligand (CDCA) and gene expression was analysed by q-PCR.

Methods

Chemicals
Cyclosporin A (CsA), chenodeoxy cholic acid (CDCA), and bovine serum albumin (BSA) were purchased from Sigma (Sigma, Zwijndrecht, the Netherlands). Williams E medium (WEM), Glutamax, penicillin/streptomycin (pen/strep), D-Glucose, phosphate buffered saline (PBS) were obtained from Invitrogen (Invitrogen, Bleiswijk, the Netherlands). Sigma (Sigma, Zwijndrecht, the Netherlands). Slices were pre-cultured in one well of the 6-well plate filled with 4 ml of WEM for one hour with continuous agitation (70 rpm). Incubations were performed in an oxygen controlled incubator (Galaxy 48 R, New Brunswick, Nijmegen, the Netherlands) at 80 % of oxygen, 5 % CO₂ and the remaining gas volume was filled up to 95 % with N₂. After one hour of pre-incubation, media were removed and replaced with fresh media containing test compounds or appropriate solvents. After incubations, samples were snap-frozen in liquid nitrogen and stored in ~80 °C for further analysis. Samples dedicated to histology were stored in 4 % formaldehyde at room temperature.

PCLS exposure
For all exposure experiments, PCLS were obtained from 5 WT and 5 FXRKO mice. Slices obtained from each biological replicate were cultured apart and each culture consisted of 3 co-incubated slices. The exposure experiments were performed at 2 days; at day 1, PCLS obtained from livers of 3 WT mice and 2 FXRKO mice were used and at day 2, PCLS obtained from livers of 2 WT mice and 3 FXRKO mice were used.

For the ATP assay and transcriptome analysis, WT-PCLS and FXRKO-PCLS were exposed to 40 μM CsA for 24 h. For histological examination, WT-PCLS and FXRKO-PCLS were exposed to 40 μM CsA for 24 h and 48 h. CsA was added to the culture medium as a stock solution in DMSO (final concentration of DMSO in the medium was 0.1 % v/v). Slices incubated with 0.1 % v/v DMSO served as control. These conditions were also used in a previous work studying the effects of CsA in mouse PCLS [11].

For q-PCR analysis, WT-PCLS and FXRKO-PCLS were exposed for 24 h to 100 μM of CDCA dissolved in the culture medium. This CDCA concentration was the same as used in a previous study investigating effects of CDCA in human PCLS [24]. PCLS incubated only in the culture medium served as control for CDCA exposure experiment.

ATP assay
To assess PCLS viability after the exposure experiments, the ATP assay was performed. For each ATP assay three co-cultured slices were placed in 400 μL Cell Lytic MT buffer (Sigma, Zwijndrecht, the Netherlands). Slices were homogenized (6500 g, 8 °C) two times for 15 s using a tissue homogenizer (Precellys 24 Bertin Technologies,
Labmakelaar Benelux B.V. Rotterdam, The Netherlands). To remove cellular debris, the homogenates were centrifuged for 5 min (14,000 g, 8 °C) and the remaining supernatant was divided into two portions of 200 μL. One portion was mixed with 100 μL of ATP lytic buffer from ATPlite kit (Perkin Elmer, Oosterhout, The Netherlands) for ATP measurements and the second portion was stored at −80 °C for protein measurements. ATP was measured as described by the manufacturer using a microplate reader (Synergy TM HT Multi Detection Microplate Reader, Biotek Instruments Inc, Abcoude, the Netherlands) with settings for luminescence 590/635 nm, top measurement, and sensitivity 230. ATP measurements were performed in technical duplicates and luminescence values were recalculated into μM ATP in total liver slices extracts.

The protein concentration was measured using the Bradford method (Protein assay, BioRad, Veenendaal, The Netherlands). Protein samples of 2 μL were diluted 80 times in PBS and measured according to the manufacturer’s protocol. BSA was used as a standard and each measurement was performed in duplicate. ATP concentration was normalized on mg of protein per slice. ATP concentration is the mean ± SD of 5 independent experiments.

Histology
Besides measurement of ATP levels, also histological analysis was performed to examine the viability of the slices after incubation. Slices were exposed for 24 and 48 h to 40 μM CsA or DMSO. For the 48 h cultures, after 24 h the culture medium was replaced with fresh medium supplemented with CsA or DMSO. After incubation, slices were fixed in 4 % buffered formaldehyde and embedded in paraffin. Next, the paraffin cross-sections were prepared and stained with haematoxylin and eosin (HE) according to Mayer’s protocol [25]. Sections of 3 independent experiments per each group were analysed and photographed under a microscope with a 100-fold magnification.

DNA microarray hybridizations
Gene expression analysis in PCLS incubated for 24 h with CsA or DMSO was performed using the HT Mouse Genome 430 PM array plate (s) using the Affymetrix GeneTitan system (Affymetrix, Santa Clara, CA, USA). RNA was extracted from co-cultured slices using the RNasy Tissue Mini Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol. RNA concentration and purity were assessed using a NanoDrop ND-1000 spectrophotometer (Isogen Ilsselstein, The Netherlands) by measuring absorption ratios at 260/280 and 230/ 280 nm. The integrity of the RNA samples was checked using the Shimadzu MultiNA Bioanalyzer (Shimadzu, Tokyo, Japan). Biotin- labelled cRNA was generated from total RNA with the Affymetrix 3’IVT Express Kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s instructions with an input of 100 ng total RNA. The Agilent Bioanalyzer (Agilent, Amstelveen, the Netherlands) and the Shimadzu MultiNA Bioanalyzer (Shimadzu, Tokyo, Japan) were used to examine the quality of cRNA to confirm that the average fragment size was according to Affymetrix’ specifications. For each sample, 7.5ug biotinylated cRNA was fragmented and hybridized in a final concentration of 0.0375 ug/μl on the Affymetrix HT Mouse genome 430 PM array (Affymetrix, Santa Clara, CA, USA). After washing and staining by the GeneTitan instrument (Affymetrix, Santa Clara, CA, USA) using the Affymetrix HWS kit for Gene Titan, absolute values of expression were calculated from the scanned array using the Affymetrix Command Console v 3.2 software. The data Quality Control was performed using the Affymetrix Expression Console v 1.1 (Affymetrix, Santa Clara, CA, USA) software to check whether all parameters met the quality specifications. The Probe Logarithmic Intensity Error Estimation (PLIER) algorithm method was used for probe summarisation [26].

In order to monitor the sample independent control and the performance of each individual sample during hybridization, hybridization controls were added to the hybridization mixture. To determine the biological variation between samples, the sample dependent controls such as internal control genes, background values, and average signals were used. In summary, all the data were within data Quality Control thresholds, according to the Affymetrix Expression Console specifications. Non-normalized data in a form of the Cell Intensity File (*.CEL) were re-annotated (EntrezGene htmg430pm_Mm_ENTREZG) and the data were RMA normalized [26]. The microarray data generated in this study were deposited to gene expression omnibus (GEO) and the GEO accession number is GSE63457 (data will be public upon acceptance of the manuscript).

Identification of significantly affected genes
To identify genes significantly affected by CsA in WT-PCLS and FXRKO-PCLS, the normalized data were log2 transformed, followed by analysis of variance (ANOVA) with Benjamini-Hochberg correction for false discovery rate (FDR). Genes were considered significant if FDR ≤ 0.05 and fold change (FC) was ≤ or ≥ 1.5 for down-or up-regulated genes respectively.

Data mining
Pathway analysis (MetaCore)
MetaCore identifies pathways using a default enrichment analysis. Genes significantly affected by CsA in WT-PCLS and FXRKO-PCLS (FDR ≤0.05) were uploaded to MetaCore for pathway analysis. The pathway analysis
was performed using Functional Ontology Enrichment/Pathways Maps default option in MetaCore for mouse. The identified pathways were considered as significantly affected by the treatment after FDR correction if FDR ≤ 0.005.

**Gene Ontology analysis (DAVID)**

Genes significantly up- or down-regulated by CsA in WT-PCLS and FXRKO-PCLS were uploaded separately to Database for Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics Resource. In DAVID, the Functional Annotation Clustering tool was used to identify over-represented up and down-regulated Gene Ontology (GO) terms [27, 28]. The Mouse Genome 430 2.0 was used as a background for the GO analysis. The GO terms after FDR correction (Benjamini-Hochberg) were selected at FDR ≤ 0.005 for further analysis and interpretation. In addition we selected genes significantly affected by CsA in WT-PCLS and FXRKO-PCLS identified in the significant GO terms for further analysis by hierarchical cluster analysis (HCA) and functional clustering (see below).

**Hierarchical clustering analysis**

The differentially expressed genes extracted from significant GO terms were analysed by hierarchical clustering analysis (HCA) using an open access bioinformatics tool Genesis (http://genome.tugraz.at/genesisserver/genesisserver_description.shtml). In the analysis gene expression values were log2 transformed and median centered, followed by HCA using average linkage clustering in Genesis.

**Gene functional clustering (STRING)**

Significant genes extracted from the significant GO terms were subjected to gene functional clustering with the open access bioinformatics tool STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) version 8.2. STRING constructs functional networks using information from known and predicted protein-protein interactions present in curated as well as experimental databases [29].

**q-PCR**

Expression of selected known and novel candidate FXR target genes was analysed in WT-PCLS and FXRKO-PCLS exposed to CDCA or control for 24 h by q-PCR. The q-PCR was performed using the Biorad CFX96 TM Real-Time Detection System (Bio-Rad, Veenendaal, The Netherlands) with the following cycling conditions: 1 min 95 °C followed by 40 cycles of 15 s 95 °C and 1 min 60 °C. Reactions were performed in 10 μl and contained 20 ng cDNA, 1× TaqMan PCR Master Mix (Applied Biosystems, Foster City, CA), and 250 nM probe and 900 nM primer (for actinβ) or 1× TaqMan gene expression assay (for the remaining genes) (Applied Biosystems, Foster City, CA). A specific primer set for actinβ (ACTB) was developed with Primer Express 1.5 (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands) and sequences were as follows, probe: TGT CCC TGT ATG CCT CTG GTC GTA CCA C, forward primer: AGC CAT GTA CGT AGC CAT CCA, and reverse primer: TCT CCG GAG TCC ATC ACA ATG. Primers for: small heterodimer protein (Shp), bile salt export pump (Bsep), fatty acid synthase (Fasn), cytochrome P450, Subfamily VIIA (Cyp7a1), acyl-Coenzyme A oxidase 2, branched chain (Acox2), acyl-Coenzyme A dehydrogenase, short/branched chain (Acadsb), ELOVL family member 6 (Elov6), mitochondrial GTPase 1 homolog (Mtgi1), aldehyde oxidase 1 (Aox1), peroxisome proliferator activator receptor delta (Pparδ), and peroxisome proliferator activated receptor gamma, coactivator 1 β (Ppargc1b) were purchased from Applied Biosystems. The commercial numbers of the Taqman assays and additional information about the tested genes is given in Additional file 1. Data were analyzed with SDS 2.0 software (Bio-Rad, Veenendaal, the Netherlands). For each sample, the RT-PCR reaction was performed in triplicate and the averages of the obtained threshold cycle values (C_T) were processed for further calculations. To check for contaminating DNA, samples without reverse transcriptase (−RT reaction) were analysed as well. For normalization ACTB was used. Relative expression was calculated with Δ (Δ (C_T))-method [30]. Expression of each gene is the mean ± SD of 5 independent experiments.

**Statistical analysis**

A Mann–Whitney (IBM SPSS Statistics version 20) was used to calculate differences between controls and slices cultured with CsA in normalized ATP content as well as to determine differences in gene expression measured by q-PCR between CDCA treated slices and controls. The cut off for statistical significance was set at a p-value ≤ 0.05.

**Results**

**Assessment of slice viability**

Viability of WT-PCLS and FXRKO-PCLS exposed to 40 μM of CsA or DMSO for 24 h was assessed by determining ATP levels normalized on total protein content. There was no statistically significant difference in the normalized ATP content between WT-PCLS and FXRKO-PCLS treated with DMSO or CsA indicating that exposure of both types of slices to 40 μM CsA did not result in cytotoxicity (Fig. 1).

To determine whether CsA treatment differentially affected WT-PCLS and FXRKO-PCLS morphology, HE staining was performed. WT-PCLS and FXRKO-PCLS
were exposed to DMSO or CsA for 24 or 48 h. There were no differences in morphology between WT-PCLS and FXRKO-PCLS cultured in the presence of DMSO for 24 and 48 h (Fig. 2a, e, c, and g respectively). There were also no differences between WT-PCLS and FXRKO-PCLS exposed to CsA for 24 and 48 h. However, the CsA treated slices developed ballooned hepatocytes in the outer layers of the slices (Fig. 2b and f, respectively). This phenotype was aggravated in both types of PCLS exposed to CsA for 48 h and there was no difference in the effect of CsA related to the number or time of appearance of ballooned hepatocytes between WT-PCLS and FXRKO-PCLS (Fig. 2d and h, respectively).

Transcriptome analysis
Total RNA from WT-PCLS and FXRKO-PCLS treated for 24 h with 40 μM of CsA or DMSO were used for DNA microarray hybridizations and array data were analysed by ANOVA with FDR correction. The analysis resulted in the identification of 1549 genes that were significantly regulated (FDR \( \leq 0.05 \), absolute FC ≥1.5) by CsA in WT-PCLS and FXRKO-PCLS in common (609 up- and 940 down-regulated) (Fig. 3a and b). It was observed that FCs in expression of these genes were comparable in both types of slices, indicating that quantitative effects of CsA were similar (GSE63457, Fig. 3c, and d). As shown in Fig. 3a and b, in addition to the genes commonly regulated by CsA in both WT-PCLS and FXRKO-PCLS, 303 genes were significantly affected only in WT-PCLS (137 up- and 166 down-regulated) and 700 genes were uniquely affected in FXRKO-PCLS (220 up- and 480 down-regulated).

Functional analysis of genes commonly regulated by CsA in WT-PCLS and FXRKO-PCLS
The significantly affected genes were subjected to pathway analysis in MetaCore. The pathway analysis of the

![Fig 1 Viability of mouse liver slices upon treatment. Slices obtained from livers of WT and FXRKO mice (denoted as WT-PCLS and FXRKO-PCLS, respectively) were incubated for 24 h with 40 μM of cyclosporin A (CsA) or vehicle control (DMSO). ATP content (nmol/mg of protein) in slices treated with CsA was compared to control slices (DMSO). Each point is the mean ± SD of 5 independent experiments. None of the measured parameters was significantly affected.]

![Fig 2 Histological analysis of liver slices treated with cyclosporin A (CsA). WT-PCLS (a-d) were cultured for 24 and 48 h in the presence of DMSO (a and c) or 40 μM CsA (b and d). FXRKO-PCLS (e-h) were cultured for 24 and 48 h in the presence of DMSO (e and g) or 40 μM CsA (f and h).]
genes commonly regulated in WT-PCLS and FXRKO-PCLS upon exposure to CsA led to identification of 29 significant pathways (18 up- and 11 down-regulated at an FDR ≤ 0.005) (Table 1). All the identified pathways were grouped into functional categories based on information provided by the MetaCore classification tool. In general, it was observed that the significantly upregulated pathways clustered into “Endoplasmic reticulum stress”, “Metabolic diseases”, and “Inflammation” and that the most significantly upregulated pathway was represented by “ER stress response pathway” (Fig. 4a, Table 1). The significantly downregulated pathways could be clustered into functional categories such as “Coagulation” and “Regulation of energy metabolism” (Table 1). Examples of these pathways were “Blood coagulation”, (Table 1) and “Bile acids regulation of glucose and lipid metabolism via FXR” (Fig. 4b, Table 1).

Next, genes significantly affected by CsA in WT-PCLS and FXRKO-PCLS were subjected to GO enrichment analysis in DAVID. The analysis identified that GO processes such as “ER”, “ER stress”, and “protein/vesicular transport” were significantly upregulated (FDR < 0.005; Fig. 5a, Table 2). While “coagulation”, “lipid metabolism”, and “protein processing” were significantly downregulated (FDR < 0.005;
Overall, the results of the GO analysis were in agreement with those of the MetaCore pathway analysis and pointed to regulation of similar biological processes including upregulation of ER stress and inflammation, and downregulation of coagulation and energy metabolism.

**Functional analysis of genes uniquely regulated in either WT-PCLS or FXRKO-PCLS**

In order to better understand the impact of Fxr deficiency on CsA treatment, the genes uniquely regulated in WT-PCLS or FXRKO-PCLS were subjected to pathway and GO analyses. The pathway analysis did not identify any significant pathways (FDR ≤ 0.005) in neither WT-PCLS nor FXRKO-PCLS. However, with regard to GO analysis, GO- processes related to “ECM” were significantly downregulated (FDR ≤ 0.005) in WT-PCLS (Table 3). In FXRKO-PCLS, GO- processes related to “inflammation” were significantly upregulated, while GO- processes related to “mitochondrion” were significantly downregulated (Table 3).

In order to gain more insight into functions of genes identified in the GO processes uniquely regulated in WT-PCLS or FXRKO-PCLS, genes significantly contributing to the GO enrichment were visualized as functional networks and heat maps. In WT-PCLS gene clusters related to development/morphogenesis and ECM components were identified (Fig. 5). In FXRKO-PCLS the genes upregulated by CsA were clustered into different
pro-inflammatory processes, such as TNF and chemokine signaling (Fig. 6), while the downregulated clusters contained several genes involved in mitochondrial processes such as \( \beta \)-oxidation, CoA metabolism, and genes of the cytochrome P450 superfamily (Fig. 7).

**Fxr deficiency and GO-terms related to mitochondrial functions**

In a further analysis we focused on genes identified in the significant GO-processes related to mitochondrial functions, which were uniquely downregulated in FXRKO-PCLS upon CsA treatment (Table 3, Fig. 7). Based on these findings, we speculated that some of these genes might play a role in FXR signaling and/or represent novel FXR target genes. To determine whether a subset of these genes is regulated by endogenous FXR ligand in an FXR dependent manner, WT-PCLS and FXRKO-PCLS were exposed to CDCA and gene expression was analysed by q-PCR. As positive controls we measured the expression of known FXR target genes such as Shp, Bsep, and Fasn in WT-PCLS treated with CDCA, Fig. 8a. As expected, in WT-PCLS, but not in FXRKO-PCLS, the known FXR target genes including Shp, Bsep, and Fasn were significantly upregulated by CDCA treatment 1.9, 2.1, and 2.1 fold, respectively (p < 0.05) (Fig. 8a-c). Surprisingly, despite significant upregulation of Shp there was no downregulation of Cyp7a1 in WT-PCLS treated with CDCA, Fig. 8d. Although the putative FXR targets i.e. Acox2 and Elovl6 tended to be upregulated by CDCA in an FXR-dependent manner, it did not reach a significant difference, Fig. 8e-f. Furthermore, it was observed that Pparδ and Ppargc1b were significantly induced by CDCA treatment in an FXR-dependent manner (2.3 and 1.9-fold respectively, p < 0.05), therefore suggesting that these genes are regulated by FXR, Fig. 8i-j.

**Discussion**

In the present study we investigated the impact of Fxr deficiency on the effects of the model hepatotoxicant CsA in mouse PCLS. It was anticipated that Fxr deficiency could aggravate the hepatotoxicity of CsA and pinpoint to novel genes/processes regulated by FXR.
Measurement of cellular ATP levels revealed that the applied CsA concentration did not affect the viability of either WT-PCLS or FXRKO-PCLS, suggesting a comparable tolerance of both types of slices to 40 μM CsA (Fig. 1). Despite application of non-toxic concentrations of CsA, its treatment triggered ballooning of hepatocytes, which indicates on induction of inflammation and apoptosis in WT-PCLS and FXRKO-PCLS (Fig. 2). However, the ballooning occurred only in the outer layers of both types of PCLS which, compared to the inner layers, likely are exposed to higher CsA concentration. These findings are in agreement with previous work showing that the same phenotype developed upon treatment of mouse PCLS with CsA [11] and indicate that the response of WT-PCLS and FXRKO-PCLS to CsA is comparable.

The transcriptome analysis showed that in both WT-PCLS and FXRKO-PCLS, CsA upregulated pathways related to ER stress, protein/vesicular transport, NFκb signaling, and inflammation (Figs. 3c and 4a, Table 1). These findings are in line with the literature reporting that CsA induces oxidative stress, unfolded protein response, and inflammation [11, 19, 32]. However, the lack of major differences in response of WT-PCLS and FXRKO-PCLS to CsA seems to be in contrast to findings of Wang and colleagues who demonstrated that Fxr-deficiency in Fxr-KO mice and human hepatocytes have significantly increased hepatotoxicity upon exposure to other inducers of oxidative stress represented by carbon tetrachloride (CCl4) and hydrogen peroxide (H2O2) respectively [33]. It was shown that oxidative stress induced by CCl4 or H2O2 inhibit the binding of FXR to

| General function | GO process | FDR  |
|------------------|------------|------|
| Upregulation     | ER         | G00005783 ~ endoplasmic reticulum | 2.8E-25 |
|                  | ER         | G00044432 ~ endoplasmic reticulum part | 4.4E-15 |
|                  | ER         | G00031974 ~ membrane-enclosed lumen | 3.0E-11 |
|                  | ER         | G00070013 ~ intracellular organelle lumen | 5.6E-10 |
|                  | ER         | G0005788 ~ endoplasmic reticulum lumen | 4.4E-09 |
|                  | ER         | G00042175 ~ nuclear envelope-endoplasmic reticulum network | 2.5E-08 |
|                  | ER         | G0005789 ~ endoplasmic reticulum membrane | 2.9E-07 |
|                  | ER         | G00012505 ~ endomembrane system | 6.6E-05 |
|                  | ER stress  | G00006986 ~ response to unfolded protein | 2.2E-04 |
|                  | ER stress  | G00034976 ~ response to endoplasmic reticulum stress | 2.2E-03 |
|                  | Protein/vesicular transport | G00045184 ~ establishment of protein localization | 8.1E-08 |
|                  | Protein/vesicular transport | G00015031 ~ protein transport | 9.7E-08 |
|                  | Protein/vesicular transport | G0008104 ~ protein localization | 5.0E-07 |
|                  | Protein/vesicular transport | G00031982 ~ vesicle | 1.3E-03 |
|                  | Protein/vesicular transport | G00016192 ~ vesicle-mediated transport | 1.7E-03 |
|                  | Protein/vesicular transport | G00046907 ~ intracellular transport | 2.1E-03 |
|                  | Protein/vesicular transport | G00016023 ~ cytoplasmic membrane-bounded vesicle | 2.1E-03 |
|                  | Protein/vesicular transport | G00031988 ~ membrane-bounded vesicle | 2.5E-03 |
|                  | Protein/vesicular transport | G00031410 ~ cytoplasmic vesicle | 4.0E-03 |
| Downreg.         | Coagulation | G00009611 ~ response to wounding | 2.4E-06 |
|                  | Coagulation | G00006956 ~ complement activation | 4.1E-06 |
|                  | Coagulation | G00006958 ~ complement activation, classical pathway | 9.8E-04 |
|                  | Lipid metabolism | G00006644 ~ phospholipid metabolic process | 5.0E-04 |
|                  | Lipid metabolism | G00016042 ~ lipid catabolic process | 8.6E-04 |
|                  | Lipid metabolism | G00006631 ~ fatty acid metabolic process | 9.6E-04 |
|                  | Lipid metabolism | G00006775 ~ fat-soluble vitamin metabolic process | 2.5E-03 |
|                  | Protein processing | G00051605 ~ protein maturation by peptide bond cleavage | 1.8E-05 |
|                  | Protein processing | G00051604 ~ protein maturation | 1.5E-04 |

GO analysis of the significant genes (FDR < 0.05) regulated by Cyclosporin A in WT-PCLS and FXRKO-PCLS. GO analysis was performed in DAVID and GO process was considered as significant if FDR < 0.005. In addition, the individual GO processes were grouped according to their general function and these groups are depicted in column denoted as “General function.”
Table 3 GO analysis of genes uniquely regulated in WT-PCLS or FXRKO-PCLS

| General process | GO process (WT-PCLS) | FDR       | Direction of change |
|-----------------|----------------------|-----------|---------------------|
| WT-PCLS         | ECM                  | GO:0031012 ~ extracellular matrix | 9.4E-10 | Downregulation      |
|                 | ECM                  | GO:0005578 ~ proteinaceous extracellular matrix | 2.0E-09 | Downregulation      |
|                 | ECM                  | GO:0044421 ~ extracellular region part | 1.5E-06 | Downregulation      |
|                 | ECM                  | GO:0005576 ~ extracellular region | 2.0E-04 | Downregulation      |
| FXRKO-PCLS      | Inflammation         | GO:0005125 ~ cytokine activity | 6.1E-05 | Upregulation        |
|                 | Inflammation         | GO:0005615 ~ extracellular space | 4.6E-03 | Upregulation        |
|                 | Inflammation         | GO:0006935 ~ chemotaxis | 9.8E-03 | Upregulation        |
|                 | Inflammation         | GO:0042330 ~ taxis | 9.8E-03 | Upregulation        |
|                 | Mitochondrial functions | GO:0005739 ~ mitochondrion | 2.0E-11 | Downregulation      |
|                 | Mitochondrial functions | GO:0048037 ~ cofactor binding | 1.5E-03 | Downregulation      |
|                 | Mitochondrial functions | GO:0044429 ~ mitochondrial part | 2.9E-03 | Downregulation      |

GO analysis of the significant genes (FDR ≤ 0.05) uniquely regulated by CsA in WT-PCLS or FXRKO-PCLS. GO analysis was performed in DAVID and GO process was considered as significant if FDR ≤ 0.005. In addition, the GO processes were grouped according to their general function and these groups are depicted in column denoted as “General function”. The last column informs whether a GO process was up- or down-regulated (“Direction of change”).

Fig 5 Functional and hierarchical clustering analysis of genes identified in GO processes related to “ECM” uniquely regulated in WT-PCLS. Genes identified in the significant GO-processes (FDR ≤ 0.005) related to “ECM” in WT-PCLS are presented as a network and a heat map. The network consists of 3 functional clusters shown as circles and denoted as: metalloproteinases (1), collagens (2), and development/morphogenesis (3). Connected nodes within the functional clusters indicate known gene-gene interactions and genes for which gene-gene interactions are unknown are presented as unconnected nodes. Thicker lines represent stronger associations between genes. Inter-cluster edges are represented by dashed lines. The heat map is the result of hierarchical clustering of log2, median centered, gene expression values in slices obtained from individual mice. Red and green indicate expression higher and lower, respectively, than the average expression of all samples within the heat map. WT stands for control (DMSO-treated) slices obtained from WT mice. WTCSA stands for CsA treated slices obtained from WT mice. KO stands for control (DMSO) slices obtained from FXRKO mice. KOCSA stands for CsA treated slices obtained from FXRKO mice.
FXRE by increased poly (ADP-ribosyl) ation of FXR catalysed by poly (ADP-ribose) polymerase 1 (PARP1), which alters FXR conformation leading to dissociation of FXR from FXRE and thereby suppresses expression of FXR target genes involved in hepatoprotection [33]. The lack of differences between FXRKO-PCLS and WT-PCLS with respect to regulation of stress response pathways and hepatotoxic effects in our study and the observations of Wang and colleagues could be explained by (i) differences in the mechanism of action between CsA and CCl\textsubscript{4}/H\textsubscript{2}O\textsubscript{2} and/or (ii) model-dependent differences. However, a recent study investigating effects of CsA in HepaRG cells showed that 50uM CsA induces oxidative stress as early as 15 min leading to irreversible alterations of efflux and uptake of BA co-occurring with disorganisation of F-actin microfilaments and bile canaliculi [34]. These early events were followed by altered expression of genes related to oxidative stress (at 6 h) and genes controlling bile acid homeostasis (at 24 h). Therefore, based on the results of Sharanek et al.[34], it could be anticipated that in our study the lack of differences in morphology between WT-PCLS and FXR-PCLS results from early and irreversible cytotoxic effects of CsA, which are gene-expression independent and cannot be compensated at later time points by potential hepatoprotective effects of FXR. From the other hand, the slightly worse hepatotoxic gene expression profile in FXRKO-PCLS vs. WT-PCLS, could reflect the disability of FXRKO-PCLS to involve the FXR-dependent hepatoprotective mechanism that controls expression of gens involved in inflammation and mitochondrial functions.

As mentioned above, we observed upregulation of several genes encoding pro-inflammatory cytokines such as IL-6, Csf3 (~3-6-fold upregulated), and IL-23. The latter gene was the most upregulated one in both types of PCLS (above 20 fold; Fig. 3c). IL-23 is produced by dendritic and Kupffer cells upon stimulation with pro-inflammatory stimuli e.g. LPS [35]. IL-23 together with IL-6 activates naive CD4+T cells to differentiate into highly pro-inflammatory Th17 cells producing IL-17 that further enhances expression of IL-1, IL-6, TNF\alpha, and NOS-2 [35]. However in our study, despite upregulation of IL-6 and IL-23, we did not observe upregulation of IL-17 in both kinds of slices upon CsA treatment. This finding indicates

*Fig. 6 Functional and hierarchical clustering analysis of genes identified in GO processes related to “inflammation” uniquely regulated in FXRKO-PCLS. Genes identified in the significant GO-processes (FDR \leq 0.005) related to “inflammation” in FXRKO-PCLS are presented as a network and a heat map. The network consists of 3 functional clusters shown as circles and denoted as: immunomodulation (1), chemokine signaling (2), and TNF signaling (3). The heat map is the result of hierarchical clustering of log2, median centered, gene expression values in slices obtained from individual mice. For explanation of the lines, spheres, the heat map, and abbreviations, see Fig. 5*
that CsA inhibited maturation of CD4+ T cells into Th17. However it is also possible that maturation of Th17 does not occur in PCLS, since CD4+ T cells might be absent in our model [36]. In this context it is noteworthy to mention that despite CsA therapy, there are patients with high serum levels of IL-23 and IL-17 suffering from acute organ rejection in contrast to patients with low serum levels of IL-23 and IL-17 who accept graft [37]. On the basis of these literature observations, it can be envisaged that in case the immunosuppressive effect of CsA (i.e. inhibition of CD4+ T/Th17 transition) is overruled by the hepatotoxic effects of CsA (i.e. stimulation of IL-23 expression), then CsA could induce the IL-23-dependent maturation of highly pro-inflammatory Th17 cells and trigger organ rejection.

Furthermore, WT-PCLS and FXRKO-PCLS significantly downregulated expression of key genes and pathways involved in regulation of energy metabolism such as Hnf4α, Lxrα, Rxrα, “Bile acids regulation of glucose and lipid metabolism via FXR”, and “PPAR pathway” (Fig. 4b, Table 1). These observations suggest that CsA can impair lipid and glucose homeostasis and are in line with literature reports linking CsA therapy with the development of metabolic diseases [15–17, 38]. These hepatotoxic effects can be related to CsA-driven upregulation of NFκb signaling and inflammation (Figs. 3c and 4a, Table 1), which are known to downregulate expression of different nuclear receptors and their target genes [24, 39, 40].

Moreover, in WT-PCLS and FXRKO-PCLS CsA significantly downregulated pathways related to coagulation
This finding is in line with previously reported occurrence of haemorrhages in patients during CsA therapy [41].

Analysis of the genes uniquely downregulated by CsA in WT-PCLS revealed GO processes related to "ECM" (Table 3, Fig. 5). The fact that this downregulation occurred only in WT-PCLS points towards different effects of CsA on cellular signaling in the presence/absence of FXR. However, it is difficult to explain its exact meaning in the context of FXR signaling due to the lack of any literature data exploring effects of FXR on genes belonging to ECM.

Specifically in FXRKO-PCLS, CsA treatment upregulated GO processes related to "inflammation" and downregulated GO processes related to "mitochondrial functions" (Table 3, Figs. 6 and 7). With regard to the upregulation of GO processes related to "inflammation", this finding is in line with known features of FXRKO mice, which display exaggerated response to pro-inflammatory stimuli [42, 43]. The significant downregulation of GO processes related to "mitochondrial functions" in FXRKO-PCLS points towards involvement of FXR in maintaining of mitochondrial functions. Consistent with this notion, recently it was reported that a synthetic FXR ligand 6-ethyl CDCA (6-ECDCA) upregulated several mitochondrial proteins in liver [44]. Moreover, Lee et al. reported that during oxidative stress, activation of FXR reduced mitochondrial dysfunction in hepatocytes [45]. Although, we did not confirm by q-PCR that the selected genes identified within the GO terms related to "mitochondrial functions" were significantly upregulated by CDCA in an FXR-dependent manner, we cannot exclude that such an upregulation could occur under certain physiological challenge (e.g. oxidative stress) or using an FXR-ligand other than CDCA. Based on our finding that the master regulator of mitochondrial functions and inflammation Ppars and its target gene Pparcg1b [31, 46, 47] were significantly upregulated by CDCA in an FXR dependent manner (Fig. 8i-j), it can be speculated that the involvement of FXR in regulation of mitochondrial functions and inflammation could occur via an FXR-PPARδ crosstalk.

With regard to the application of mouse WT-/FXRKO-PCLS to study FXR signaling in the liver, this model seems to have some limitations. Although selected known FXR target genes, such as Shp, Bsep, and Fasn were significantly upregulated by CDCA in an FXR-dependent manner, we did not observe a downregulation of Cyp7a1 (despite significant upregulation of Shp). This finding indicates that PCLS might lack other factors involved in Cyp7a1 inhibition such as intestinal Fgf15 [48]. A similar phenomenon
was observed in regulation of NTCP in human PCLS, where despite upregulation of SHP by CDCA, no repression of NTCP occurred [24]. These observations indicate that PCLS may not be suitable to study genes regulated by trans-repression and/or cross-talk with extrahepatic tissues. However, our finding that Cyp7a1 basal expression was clearly higher in FXRKO-PCLS compared to WT-PCLS (Fig. 8d), indicates that features of FXRKO mouse are also preserved in PCLS [23].

Conclusions

In summary, our study shows that, although FXR plays a central role in regulation of energy metabolism, no major differences in response to CsA could be observed between WT-PCLS and FXRKO-PCLS in regulation of processes involved in lipid and glucose metabolism. This finding indicates that CsA does not directly affect FXR functions in relation to the above mentioned processes. However, the CsA-induced upregulation of additional pro-inflammatory genes/processes and the downregulation of genes/processes involved in mitochondrial functions in FXRKO-PCLS only, indicate that FXR can be hepatoprotective by controlling inflammation and mitochondrial functions, possibly involving a crosstalk between FXR and PPARα.

Additional file

Additional file 1: Validation of known and putative Fxr target genes by q-PCR. Information about primers and functions of genes used in q-PCR to test expression of known and novel putative Fxr target genes in WT-PCLS and FXRKO-PCLS exposed to endogenous FXR ligand. Numbers of Taqman assays are given in column "Taqman assay". Information about functions of the tested genes is according to Gene Cards. http://www.genecards.org/ (PPTX 103 kb)

Abbreviations

FXR: Farnesoid X receptor; PCLS: Precision cut liver slices; KO: Knockout; WT: Wild type; CsA: Cyclosporin A; BA: Bile acids; CDCA: Chenodeoxycholic acid; PPAR: Peroxisome proliferator-activated receptor; RXR: Retinoid X receptor; FXXR: Farnesoid X receptor response elements; BSEP: Bile salt export pump; BAAT: Bile acid-CoA amino acid N-acyltransferase; MDR3: Multidrug resistance protein 3; Cyp7a1: Cholesterol-7a-hydroxylase; Shp: Small heterodimer partner; Lth1: Liver receptor homolog-1; Lxr: Liver X receptor; Hnf4α: Hepatocyte nuclear factor 4 α; Pepck: Phosphoenolpyruvate carboxykinase; G6Pase: Glucose 6-phosphatase; ER: Endoplasmatic reticulum; (NF)β: Nuclear factor β; PBS: Phosphate buffered saline; DMSO: Dimethyl sulfoxide; KHb: Krebs-Henseleit buffer; HEPE: (4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid); GO: Gene ontology; DAVID: The database for annotation, visualization, and integrated discovery; FDR: False discovery rate; SD: Standard deviation; RMA: Robust Multiarray Average; HCA: Hierarchical clustering analysis; PARP1: Poly (ADP-ribose) polymerase 1; ADP: Adenosine diphosphate; CCL4: Carbon tetrachloride; H2O2: Hydrogen peroxide.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ESZ designed the study, analysed data, and wrote the manuscript. TP provided bioinformatics support. AACMP contributed to the study design and preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgment

We would like to thank Folkert Kuipers for a kind donation of FXRKO and WT mice, Juul Baller and Angelika Jurzinski for assistance in transfer of the animals, Judith Hulsman for assistance in handling of the animals, as well as Maria Groot and Jan Ossenkoppele for carrying out the histological experiments.

Funding

This work was supported by the Netherlands Genomics Initiative, the Netherlands Organisation for Scientific Research, and the Netherlands Toxicogenomics Centre (grant number 05060510).

Author details

1RIKILT - Institute of Food Safety/Wageningen UR, Akkerraamsluis 2, P.O. Box 2306700 AE Wageningen, The Netherlands. 2Centre for Health Protection, National Institute for Public Health and the Environment (GIZB, RIVM), Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, The Netherlands. 3RikILT-Institute of Food Safety/Wageningen UR, Akkerraamsluis 2, 6708 WB Wageningen, The Netherlands.

Received: 26 November 2014 Accepted: 12 October 2015

Published online: 20 October 2015

Page 15 of 16

References

1. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene. 2002;290(1–2):35–43.
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147–91.
3. Porez G, Pravitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53(9):1723–37.
4. Sinal CJ, Tolkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/GR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–44.
5. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Greffhorst A, van Dijk TH, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem. 2003;278(33):30971–9.
6. Stayrock KK, Bramlett KS, Sawk RS, Ficorilli J, Cook T, Christe ME, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146(3):984–91.
7. Meng Z, Wang Y, Wang L, Jin W, Liu N, Pan H, et al. FXR regulates liver repair after CCA-inducing toxic injury. Mol Endocrinol. 2010;24(5):886–97.
8. De Graaff I, Ollinga P, De Jager MH, Merema MT, De KR, Van Der Kerkhof EG, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. NatProtoc. 2010;5(5):1540–51.
9. Fiorucci S, Cipriani S, Mengarelli A, Renga B, Distrutti E, Baldelli F. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med. 2011;10(8):579–95.
10. Li Z, Kruit JK, van der Sluis RJ, van Berkel TJ, Hoekstra M. Nuclear receptor atlas of female mouse liver parenchymal, endothelial, and Kupffer cells. Physiol Genomics. 2013;45(7):268–75.
11. Szalowska E, Stoopen G, Groot MJ, Hendriksen D, Van Der Kerkhof EG, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. NatProtoc. 2010;5(5):1540–51.
12. Calne RY. Immunosuppression for organ grafting – observations on cyclosporin A. Immunol Rev. 1979;61:13–24.
13. Bennett WM, Norman DJ. Action and toxicity of cyclosporine. Annu Rev Med. 1986;37:215–24.
14. Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. HistolHistopathol. 2006;21(3):301–16.
15. Dandel M, Lehmkhul HB, Knosa I, Hetzer R. Impact of different long-term maintenance immunosuppressive therapy strategies on patients’ outcome after heart transplantation. Transplimmunol. 2010;23(3):109–103.
16. Pagadala M, Dasarathy S, Eightsad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transplant. 2009;15(12):1662–70.
17. Hulzebos CV, Bijleveld CM, Stellaard F, Kuipers F, Fidler V, Slooff MJ, et al. Cyclosporine A-induced reduction of bile salt synthesis in patients with cirrhosis. Liver Transplant. 2004;10(7):1782–7.

18. Wolf A, Trendelenburg CF, Ez Fernandez C, Prieto P, Houy S, Trommer WE, et al. Cyclosporine A-induced oxidative stress in rat hepatocytes. JPharmacolExpTher. 1997;280(2):328–34.

19. van Summeren A, Reens J, Bouwman FG, Noben JP, van Delft JH, Kleinjans JC, et al. Proteomic investigations of drug-induced hepatotoxicity in HepG2 cells. ToxicolSci. 2011;120(1):109–22.

20. Barth A, Braun J, Muller D. Influence of Verapamil and Cyclosporin A on bile acid metabolism and transport in rat liver slices. ExpToxicolPathol. 2006;58(1):31–7.

21. Chanuost F, Benkel F. Prevention by dietary (n-6) polyunsaturated phosphatidylinolines of intrahepatic cholestasis induced by cyclosporine A in animals. Life Sci. 2003;73(4):381–92.

22. Kienhus A, Vitins AP, Pennings JL, Pronk TE, Spekensjerd EN, Roobbergen M, et al. Cyclosporin A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis. Toxicol Lett. 2013;221(3):225–36.

23. Kok T, Hulzebos CV, Wolters H, Havinnga R, Angelon LB, Stellaard F, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile-acid-binding protein. BioChem. 2003;78(34):41930–7.

24. Jung D, Effenik MG, Stellaard F, Groothuis GM. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int. 2007;27(1):137–44.

25. Groot MJ, Ossenkoppele JS, Bakker R, Pfaffl MW, Meyer HH, Nielen MW. Reference histology of veal calf genital and endocrine tissues - an update for screening on hormonal growth promoters. J VetMedA Physiol PatholClinMed. 2007;54(5):238–46.

26. Qu Y, He F, Chen Y. Different effects of the probe summarization algorithms: PLIER and RMA on high-level analysis of Affymetrix exon arrays. BMCBioinformatics. 2010;11:211.

27. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):3.

28. da Huang W, Sherman BT, Lemppicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

29. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808–15.

30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC(T) Method. Methods. 2001;25(4):402–8.

31. Reilly SM, Lee CH. PPAR delta as a therapeutic target in metabolic disease. FEBS Lett. 2008;582(1):26–31.

32. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. Hepatol. 2011;54(4):795–809.

33. Wang C, Zhang F, Wang L, Zhang Y, Li X, Huang K, et al. Poly(ADP-ribose) polymerase 1 promotes oxidative-stress-induced liver cell death via suppressing farnesoid X receptor alpha. Mol Cell Biol. 2013;33(22):4492–503.

34. Sharanek A, Azzi PB, Al-Attrache H, Savary CC, Humbert L, Rainteau D, et al. Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells. Toxicol Sci. 2014;141(1):244–53.

35. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol. 2013;2013:968549.

36. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. DigDis. 2010;28(1):131–44.

37. Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/Interleukin-23 during acute rejection in liver transplantation. Liver Transplant. 2009;15(6):629–33.

38. Krentz AJ, Dousset B, Bayer D, McMaster P, Buckels J, Crumb R, et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes. 1993;42(11):1753–9.

39. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J Biol Chem. 2003;278(11):9888–95.

40. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metab Clin Exp. 2007;56(2):267–79.

41. Wang WL, Yang ZF, Lo CM, Liu CL, Fan ST. Intracellular hemorrhage after liver transplantation. Liver Transplant. 2000;6(3):345–8.

42. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48(5):1632–43.

43. Zhang S, Wang J, Liu Q, Hamish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):380–9.

44. Gardino C, Tamburo A, Modica S, Moschetta A. Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim Biophys Acta. 2011;1812(8):836–41.

45. Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, et al. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology. 2012;142(5):1206–17, e1207.

46. Serrano-Marco L, Baroso E, El Kochairi I, Palomer X, Michalik L, Wahi W, et al. The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia. 2012;55(3):743–51.

47. Staels B, Rubenstunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH. Hepatology. 2013;58(6):1941–52. doi:10.1002/hep.26461. Epub 2013 Oct 29.

48. Claudel T, Zollner G, Wagner M, Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta. 2011;1812(8):867–78.